TOKYO, Jul 01 (Pulse News Wire) – Wolves Hand CO.,LTD. (194A.T) resolved at a special board meeting held on July 01 to acquire all shares of Meditrix Corporation, aiming to strengthen its research and development capabilities within the "One Health" framework.
Meditrix specializes in clinical trial support services and possesses extensive knowledge in data management, which Wolves Hand expects to enhance its ability to commercialize research outcomes. The acquisition will bolster Wolves Hand's value chain from theme creation through productization and social implementation. Key synergies include leveraging Meditrix’s expertise to improve development efficiency and market entry speed for medical devices developed by subsidiary Aoi Medical.
Additionally, Meditrix will aid in advancing clinical studies related to biomaterials and advanced healthcare technologies, supporting the integration of animal health initiatives into human healthcare applications. Meditrix was established on January 30, 2007, with a capital of ¥34.9 million. The transaction details remain undisclosed due to confidentiality agreements but are expected to conclude on July 03, 2026, subject to regulatory approvals.
Wolves Hand anticipates accelerating its One Health platform's competitive advantage through this strategic move.
🟡 Confidence: Standard AI-translated content.